Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
Site Search
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
A group of nonpartisan patient and consumer organizations issued a statement after passage of the Tax Cuts and Jobs Act.
This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Twelve patient/consumer groups urge senate to reject the bill.
Responding to the U.S. Department of Health and Human Services final rule on short-term, limited-duration insurance plans, the Cystic Fibrosis Foundation joined 26 other nonpartisan patient and consumer groups to voice concern that these plans will split the market and jeopardize access to affordable, adequate health care for people living with pre-existing conditions.
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation